Novo Nordisk的试验显示 Wegovy改善了患有代谢性肝病的成年人的肝脏健康。 Novo Nordisk's trial showed Wegovy improves liver health in adults with metabolic liver disease.

诺沃诺迪斯克报告了ESSENCE第三期试验的第一部分的积极结果,评估了2. 4毫克的西马格卢提德 (Wegovy) 于1, 200名患有代谢功能障碍相关的脂肪肝炎 (MASH) 和肝纤维化的成年人. Novo Nordisk reported positive results from the first part of the ESSENCE Phase 3 trial, evaluating semaglutide 2.4 mg (Wegovy) in 1,200 adults with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. 与安慰剂相比,该研究显示肝纤维化和脂肪肝炎的消失显著改善. The study showed significant improvements in liver fibrosis and resolution of steatohepatitis compared to placebo. Novo Nordisk计划到2025年年中在美国和欧盟寻求监管批准,预计2024年将取得更详细的结果。 Novo Nordisk plans to seek regulatory approvals in the U.S. and EU by mid-2025, with more detailed results anticipated in 2024.